Pricing and Reimbursement Application Tracker
Login
Search
selpercatinib (Retsevmo®)
Application Details
HSE Application ID
HSE100051
HTA Number
25034a
HTA Link
https://www.ncpe.ie/selpercatinib-retsevmo-for-advanced-ret-mutant-medullary-thyroid-cancer-hta-id-25034a/
Drug
selpercatinib
Brand
Retsevmo®
Applicant
Eli Lilly
Indication Applied For
Indicated for the treatment of adults and adolescents 12 years and older with advanced rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC).
Application Date
27/06/2025
Marketing Authorisation Date
02/09/2022
Application Status
Awaiting Proposal from Applicant
23/10/2025
Applicant Meeting Held with CPU
23/10/2025
Full Health Technology Assessment Commissioned by HSE
30/07/2025
Rapid Review Completed
01/07/2025
Pricing and Reimbursement Application Complete
27/06/2025
Rapid Review Commissioned
15/05/2025
New Search
Status
Pricing and Reimbursement Application Complete
Rapid Review Commissioned
Rapid Review Completed
Applicant Meeting Held with CPU
Awaiting Proposal from Applicant
Proposal from Applicant Under Review
Full Health Technology Assessment Commissioned by HSE
NCPE Assessment Completed
HSE Drugs Group Review Pending
Reviewed by HSE Drugs Group
HSE Rare Disease Technology Review Committee - Review Requested
HSE Rare Disease Technology Review Committee - Review Received
Further Information Requested by HSE Drugs Group
Reviewed by HSE Senior Leadership Team
Managed Access Protocol (MAP) Commissioned
Proposed HSE Decision Issued to Applicant
Applicant Representations Received
HSE Decision Issued to Applicant
Application On Hold at the Request of Applicant
Application Withdrawn at the Request of Applicant
HSE Approval Letter Issued to Applicant
Full Health Technology Assessment Submitted to NCPE
Delete Application
×
Are you sure you want to delete this Application?
Once it's deleted it cannot be retrieved.
Remove Status and Date
×
Are you sure you want to delete this?